Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.

M. Artico,A. Mai,G. Sbardella,S. Massa,C. Musiu,S. Lostia,F. Demontis,P. la Colla

DOI: https://doi.org/10.1016/S0960-894X(99)00251-6

IF: 2.94

1999-06-21

Bioorganic & Medicinal Chemistry Letters

Abstract:

What problem does this paper attempt to address?

Mitochondrial DNA sequences and transcriptomic profiles for elucidating the genetic underpinnings of cisplatin responsiveness in oral squamous cell carcinoma

Amnani Aminuddin,Pei Yuen Ng,Eng Wee Chua

DOI: https://doi.org/10.1186/s12863-022-01062-w

2022-06-22

BMC Genetics

Abstract:Functional genetic variation plays an important role in predicting patients' response to chemotherapeutic agents. A growing catalogue of mitochondrial DNA (mtDNA) alterations in various cancers point to their important roles in altering the drug responsiveness and survival of cancer cells. In this work, we report the mtDNA sequences, obtained using a nanopore sequencer that can directly sequence unamplified DNA, and the transcriptomes of oral squamous cell carcinoma (OSCC) cell lines with differing responses to cisplatin, to explore the interplay between mtDNA alterations, epigenetic regulation of gene expression, and cisplatin response in OSCC.

genetics & heredity
Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell.

Wei Yu,Chengmeng Jin,Xiaoyan Lou,Xu Han,Lisha Li,Yinghua He,Hongyu Zhang,Kelong Ma,Jingde Zhu,Lihua Cheng,Biaoyang Lin

DOI: https://doi.org/10.1371/journal.pone.0029450

IF: 3.7

2011-01-01

PLoS ONE

Abstract:Cisplatin resistance is one of the major reasons leading to the high death rate of ovarian cancer. Methyl-Capture sequencing (MethylCap-seq), which combines precipitation of methylated DNA by recombinant methyl-CpG binding domain of MBD2 protein with NGS, global and unbiased analysis of global DNA methylation patterns. We applied MethylCap-seq to analyze genome-wide DNA methylation profile of cisplatin sensitive ovarian cancer cell line A2780 and its isogenic derivative resistant line A2780CP. We obtained 21,763,035 raw reads for the drug resistant cell line A2780CP and 18,821,061reads for the sensitive cell line A2780. We identified 1224 hyper-methylated and 1216 hypomethylated DMRs (differentially methylated region) in A2780CP compared to A2780. Our MethylCap-seq data on this ovarian cancer cisplatin resistant model provided a good resource for the research community. We also found that A2780CP, compared to A2780, has lower observed to expected methylated CpG ratios, suggesting a lower global CpG methylation in A2780CP cells. Methylation specific PCR and bisulfite sequencing confirmed hypermethylation of PTK6, PRKCE and BCL2L1 in A2780 compared with A2780CP. Furthermore, treatment with the demethylation reagent 5-aza-dC in A2780 cells demethylated the promoters and restored the expression of PTK6, PRKCE and BCL2L1.
Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Li Yinyan,Wang Xiujun

DOI: https://doi.org/10.11844/cjcb.2013.07.0019

2013-01-01

Abstract:Cisplatin,carboplatin and oxaliplatin have been used clinically for treatment of many types of cancers,including ovarian,cervical,lung,colorectal cancer and relapsed lymphoma.Platinum-DNA adducts are formed following the uptake of the drug into the cell nucleus.As a result,DNA structure is changed,leading to the disorder of DNA replication and transcription,and eventually the cell death.Treatment with platinum agents is characterized by resistance and toxicity through activating a number of signal transduction pathways.This article highlights recent discoveries in cellular pathways responsive to the platinum agents,and provides a molecular basis for understanding the differences in clinical application,cytotoxicity and drug resistance among the platinum anticancer drugs.
Nuclear TOP1MT Confers Cisplatin Resistance via Pseudogene in HNSCC

T. Tong,P. S. Zhai,X. Qin,Z. Zhang,C. W. Li,H. Y. Guo,H. L. Ma

DOI: https://doi.org/10.1177/00220345241272017

2024-10-10

Journal of Dental Research

Abstract:Journal of Dental Research, Ahead of Print. Cisplatin resistance is one of the major causes of treatment failure in head and neck squamous cell carcinoma (HNSCC). There is an urgent need to uncover the underlying mechanism for developing effective treatment strategies. A quantitative proteomics assay was used to identify differential proteins in cisplatin-resistant cells. Mitochondrial topoisomerase I (TOP1MT) localization was determined using laser confocal microscopy and nucleocytoplasmic separation assay. Chromatin immunoprecipitation sequencing, dual-luciferase reporter assay, and RNA immunoprecipitation were used to identify the interaction between pseudogenes, miRNAs, and real genes. In vivo experiments verified the interaction between TOP1MT and pseudogenes on cisplatin resistance. TOP1MT was identified as a driving factor of cisplatin resistance in vitro, in vivo, and in HNSCC patients. Moreover, TOP1MT exceptionally translocated to the nucleus in cisplatin-resistant HNSCC cells in a signal peptide–dependent manner. Nuclear TOP1MT (nTOP1MT) transcriptionally regulated the mitochondrial functional pseudogene MTATP6P1, which bound to miR-137 and miR-491-5p as a competing endogenous RNA (ceRNA) and promoted the expression of MTATP6. An increase in MTATP6 enhanced mitochondrial oxidative phosphorylation (OXPHOS), which conferred cisplatin resistance in HNSCC. Our findings revealed that nTOP1MT transcriptionally activated MTAPT6P1 and increased MTATP6 expression via ceRNA, which facilitated OXPHOS and cisplatin resistance. These results provide novel insight for overcoming cisplatin resistance in HNSCC.

dentistry, oral surgery & medicine
PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis

Luyan Shen,Boyang Sun,Jiyao Sheng,Sihang Yu,Yanqing Li,Huadan Xu,Jing Su,Liankun Sun

DOI: https://doi.org/10.3892/ijo.2018.4401

Abstract:The induction of lesions in nuclear and mitochondrial DNA by cisplatin is only a small component of its cytostatic/cytotoxic activity. The signaling pathway network in the nucleus and cytoplasm may contribute to chemotherapeutic resistance. Peroxisome proliferator-activated receptor-coactivator 1α (PGC1α)-mediated mitochondrial biogenesis regulates mitochondrial structural and the functional adaptive response against chemotherapeutic stress, and may be a therapeutic target. However, this regulatory network is complex and depends upon tumor types and environments, which require further investigation. Our previous study found that cisplatin-resistant ovarian epithelial carcinoma was more dependent on mitochondrial aerobic oxidation to support their growth, suggesting the association between mitochondrial function and chemotherapeutic resistance. In the present study, it was demonstrated that the expression of PGC1α and level of mitochondrial biogenesis were higher in cisplatin-resistant SKOV3/DDP cells compared with cisplatin-sensitive SKOV3 cells. Furthermore, SKOV3/DDP cells upregulated the expression of PGC1α and maintained mitochondrial structural and functional integrity through mitochondrial biogenesis under cisplatin stress. Inhibiting the expression of PGC1α using short hairpin RNA led to the downregulation of mitochondrial biogenesis and high levels of apoptosis in the SKOV3/DDP cells, and cisplatin resistance was reversed in the PGC1α-deficient SKOV3/DDP cells. Collectively, the present study provided evidence that cisplatin stimulated the expression of PGC1α and the upregulation of mitochondrial biogenesis through PGC1α, promoting cell viability and inhibiting apoptosis in response to cisplatin treatment, thus triggering cisplatin resistance in ovarian cancer cells.
Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells

Markus Kleih,Kathrin Böpple,Meng Dong,Andrea Gaißler,Simon Heine,Monilola A. Olayioye,Walter E. Aulitzky,Frank Essmann

DOI: https://doi.org/10.1038/s41419-019-2081-4

2019-11-01

Cell Death and Disease

Abstract:Abstract Patients with high-grade serous ovarian cancer (HGSC) frequently receive platinum-based chemotherapeutics, such as cisplatin. Cisplatin binds to DNA and induces DNA-damage culminating in mitochondria-mediated apoptosis. Interestingly, mitochondrial DNA is critically affected by cisplatin but its relevance in cell death induction is scarcely investigated. We find that cisplatin sensitive HGSC cell lines contain higher mitochondrial content and higher levels of mitochondrial ROS (mtROS) than cells resistant to cisplatin induced cell death. In clonal sub-lines from OVCAR-3 mitochondrial content and basal oxygen consumption rate correlate with sensitivity to cisplatin induced apoptosis. Mitochondria are in two ways pivotal for cisplatin sensitivity because not only knock-down of BAX and BAK but also the ROS scavenger glutathione diminish cisplatin induced apoptosis. Mitochondrial ROS correlates with mitochondrial content and reduction of mitochondrial biogenesis by knock-down of transcription factors PGC1α or TFAM attenuates both mtROS induction and cisplatin induced apoptosis. Increasing mitochondrial ROS by inhibition or knock-down of the ROS-protective uncoupling protein UCP2 enhances cisplatin induced apoptosis. Similarly, enhancing ROS by high-dose ascorbic acid or H 2 O 2 augments cisplatin induced apoptosis. In summary, mitochondrial content and the resulting mitochondrial capacity to produce ROS critically determine HGSC cell sensitivity to cisplatin induced apoptosis. In line with this observation, data from the human protein atlas ( www.proteinatlas.org ) indicates that high expression of mitochondrial marker proteins (TFAM and TIMM23) is a favorable prognostic factor in ovarian cancer patients. Thus, we propose mitochondrial content as a biomarker for the response to platinum-based therapies. Functionally, this might be exploited by increasing mitochondrial content or mitochondrial ROS production to enhance sensitivity to cisplatin based anti-cancer therapies.

cell biology
Impairment of Drug Response Cascades, by DNA Methylation, in Platinum-Resistant Ovarian Cancer.

Curtis Balch,Dhaval Desai,Meng Li,John S. Montgomery,Henry Paik,Pearlly S. Yan,Tim H-M. Huang,Kenneth P. Nephew

IF: 11.2

2007-01-01

Cancer Research

Abstract:AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 2867 To examine mechanisms of ovarian cancer development of platinum resistance, we developed a model culture system demonstrating stepwise adaptation of increasingly chemoresistant clones of the initially drug-sensitive cell line A2780. Specifically, DNA was isolated for genome-wide assessment of promoter DNA methylation, using a microarray approach known as differential methylation hybridization (DMH), to determine the relationship of this epigenetic phenomenon to drug resistance. Using DMH, global methylation of A2780 genomic DNA, following each selection cycle, was compared to DNA methylation of initially untreated (and chemosensitive) single clones. The total number of methylated (defined by a 1.5-fold hybridization difference) loci was found to increase following 1, 3, and 5 cycles of cisplatin treatment (590, 870, and 1176 loci, respectively). Moreover, a linear correlation between those increases in methylated loci and cisplatin resistance (as determined by IC50 dose) was also observed (R=0.98; P<0.001, Spearman analysis). Using the bioinformatics tool Pathway Express (Onto-Tools), we identified specific cascades altered by DNA methylation following 1, 3, and 5 cycles of cisplatin treatment. Notably, methylation of apoptosis (0, 2, and 7 genes, respectively, after 1, 3, and 5 cycles) and cell cycle (5, 7, and 11 genes) pathway components increased linearly with drug resistance, strongly suggesting that DNA methylation, and subsequent disruption, of those signaling cascades plays a prominent role in the development of insensitivity to platinum drugs. Finally, based on sequence information of chemoresistance-associated methylated loci, we used additional bioinformatics approaches to identify transcription factor-binding sites associated with those loci, examining the possibility of methylation-induced direct obstruction of transcription machinery as a means of gene silencing. In summary, we believe that these computational approaches will allow the generation of “epigenetic models” of ovarian cancer drug resistance that could provide for novel strategies for managing this devastating clinical phenomenon.
Negotiated Interfaces for Software Reuse

G. S. Novak,F. N. Hill,Man Wan,B. Sayrs

DOI: https://doi.org/10.1109/32.148482

1992-07-01

Abstract:A significant barrier to the reuse of software is the rigid interface presented by a subroutine. For nontrivial data structures, it is unlikely that the existing form of the data of an application will match the requirements of a separately written subroutine. The authors describe two methods of interfacing existing data to a subroutine: generation of a program to convert the data to the form needed by the subroutine, and rewriting the subroutine, through compilation, to fit the existing data. Both methods can be invoked through easily used menu-based negotiation with the user. These methods have been implemented using the GLISP language and compiler. >
Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy

Jolanta Kryczka,Jakub Kryczka,Karolina H. Czarnecka-Chrebelska,Ewa Brzeziańska-Lasota

DOI: https://doi.org/10.3390/ijms22168885

IF: 5.6

2021-08-18

International Journal of Molecular Sciences

Abstract:Cancer cells utilise several mechanisms to increase their survival and progression as well as their resistance to anticancer therapy: deregulation of growth regulatory pathways by acquiring grow factor independence, immune system suppression, reducing the expression of antigens activating T lymphocyte cells (mimicry), induction of anti-apoptotic signals to counter the action of drugs, activation of several DNA repair mechanisms and driving the active efflux of drugs from the cell cytoplasm, and epigenetic regulation by microRNAs (miRNAs). Because it is commonly diagnosed late, lung cancer remains a major malignancy with a low five-year survival rate; when diagnosed, the cancer is often highly advanced, and the cancer cells may have acquired drug resistance. This review summarises the main mechanisms involved in cisplatin resistance and interactions between cisplatin-resistant cancer cells and the tumour microenvironment. It also analyses changes in the gene expression profile of cisplatin sensitive vs. cisplatin-resistant non-small cell lung cancer (NSCLC) cellular model using the GSE108214 Gene Expression Omnibus database. It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Furthermore, it illustrates the multifactorial nature of cisplatin resistance by examining the diversity of dysregulated pathways present in cisplatin-resistant NSCLC cells based on KEGG pathway analysis.

biochemistry & molecular biology,chemistry, multidisciplinary
A Genome Wide CRISPR Profiling Approach Identifies Mechanisms of Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma.

Megan Ludwig,Andrew Birkeland,Joshua Smith,Elizabeth Gensterblum-Miller,JIngyi Zhai,Aditi Kulkarni,Hui Jiang,Chad Brenner

DOI: https://doi.org/10.21203/rs.3.rs-3922565/v1

2024-01-01

Abstract:Background:Head and neck squamous cell carcinoma (HNSCC) is a lethal disease with poor survival rates, especially for cancers arising in the oral cavity or larynx. Cisplatin is a key chemotherapeutic for HNSCC; however poor survival rates may be partially due to cisplatin resistance observed in some HNSCCs. Here, we examined the utility of genome-wide CRISPR knockout profiling for nominating pivotal mechanisms of cisplatin resistance in HNSCC models. Methods:We characterized the cisplatin sensitivity of 18 HNSCC cell lines. Next, we used a genome-wide CRISPR/Cas9 library to identify genes involved in cisplatin resistance. We next performed validation assays in the UM-SCC-49 cell line model. Results:Our data prioritized 207 genes as pivotal for cisplatin resistance in HNSCC, including novel genes VGLL3, CIRHA1, NCOR1, SPANXA1, MAP2K7, ULK1, and CDK16. Gene set enrichment analysis identified several NOTCH family genes comprising the top pathway driving cisplatin resistance, which we then validated using a targeted NOTCH1 knockout model. Interestingly, we noted that HNSCC models with natural NOTCH pathway alterations including single allele mutations and/or frameshift alterations had diverse responses to cisplatin treatment suggesting that complex and multi-faceted mechanisms contribute to cisplatin resistance in HNSCC. Conclusions:Collectively, our study validates a genome-wide CRISPR/Cas9 approach for the discovery of resistance mechanisms in HNSCC, adds to the growing evidence that NOTCH1 status should be evaluated as a biomarker of cisplatin response and provides a framework for future work aimed at overcoming cisplatin resistance.
Molecular mechanisms of cisplatin resistance

L Galluzzi,L Senovilla,I Vitale,J Michels,I Martins,O Kepp,M Castedo,G Kroemer

DOI: https://doi.org/10.1038/onc.2011.384

IF: 8.756

2011-09-05

Oncogene

Abstract:Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA–cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Proteomic Analyses of Sirt1-Mediated Cisplatin Resistance in OSCC Cell Line

Ping Xiong,Yu-xuan Li,Yun-tao Tang,Hong-gang Chen

DOI: https://doi.org/10.1007/s10930-011-9354-9

2011-09-24

The Protein Journal

Abstract:Oral squamous cell carcinoma (OSCC) accounts for about 90% of malignant oral lesions, and is recognized as the third most common cancer in developing nations and the sixth most common cancer worldwide. While chemotherapy remains the primary treatment for both resectable and advanced OSCC, most OSCC are naturally resistant to anticancer drugs, rendering new therapeutic avenues in dire need. Sirt1, a class III histone deacetylase, was linked to cisplatin resistance in several cancer types; however, the underlying mechanism is still unclear. Here, we demonstrated that overexpression of Sirt1 survived OSCC cell line Tca8113 under cisplatin treatment. Notably, BML-210, a chemical inhibitor of class III histone deacetylase, significantly abolished Sirt1-mediated cisplatin resistance in Tca8113 cells. Further, inactivation of endogenic Sirt1 by nicotinamide markedly increased chemo-sensitivity in cisplatin resistant sub-cell line Tca8113/CDDP. Proteomic strategy was applied to profile the differentially expressed proteins between pcDNA3.1-Sirt1- and mock vector-treated Tca8113 cells. Among 54 spots identified, 31 proteins were up-regulated and 23 proteins were down-regulated upon Sirt1 expression. Expression of four proteins with most significant alteration, including Annexin A4, Stathmin, SOD2 and thioredoxin, were validated by both RT-PCR and Western blot. Finally, we showed that Sirt1 could prevent cisplatin-induced ROS accumulation in Tca8113 cells. Our findings are considered as a significant step toward a better understanding of Sirt1-mediated cisplatin resistance.

biochemistry & molecular biology
Long-Term Cisplatin Exposure Promotes Methylation of the OCT1 Gene in Human Esophageal Cancer Cells

Rui Lin,Xiaoli Li,Jiansheng Li,Lianfeng Zhang,Feng Xu,Yanjun Chu,Jichang Li

DOI: https://doi.org/10.1007/s10620-012-2424-9

2012-10-06

Digestive Diseases and Sciences

Abstract:BackgroundCisplatin-based chemotherapy is widely used for treatment of a variety of human malignant solid and metastatic tumors, including esophageal cancer. However, the clinical effect of this drug is limited because of intrinsic and acquired resistance to it. Organic cation transporters (OCTs) are important in the cellular uptake of cisplatin.AimOur objective was to test the hypothesis that cisplatin resistance is associated with alteration of expression of OCTs.MethodsLevels of expression of OCTs in paired esophageal cancer and adjacent non-cancerous tissues were examined by use of immunohistochemistry.ResultsWe found that OCT1 silencing impaired cisplatin-mediated apoptosis of esophageal cancer cells. The level of OCT1 mRNA in cisplatin-resistant cells was markedly reduced compared with parental cells. Promoter methylation of OCT1 was induced in cisplatin-resistant cells.ConclusionThis study shows that long-term exposure to cisplatin promotes methylation of the OCT1 gene in human esophageal cancer cells, which in turn results in cisplatin resistance.

gastroenterology & hepatology
The role of microRNA in cisplatin resistance or sensitivity

Shanshan Wang,Ming-Yue Li,Yi Liu,Alexander C Vlantis,Jason YK Chan,Lingbin Xue,Bao-Guang Hu,Shucai Yang,Mo-Xian Chen,Shaoming Zhou,Wei Guo,Xianhai Zeng,Shuqi Qiu,C Andrew van Hasselt,Michael CF Tong,George G Chen

DOI: https://doi.org/10.1080/14728222.2020.1785431

IF: 6.797

2020-07-07

Expert Opinion on Therapeutic Targets

Abstract:Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor recurrence.Different mechanisms contribute to cisplatin resistance or sensitivity, involving multiple pathways or/and processes such as DNA repair, DNA damage response, drug transport, and apoptosis. Among the various mechanisms, it appears that microRNAs play an important role in determining the resistance or sensitivity. In this article, we analyzed and summarized recent findings in this area, with the aim that these data can aid further research and understanding, leading to the eventual reduction of cisplatin resistance.microRNAs can positively or negatively regulate cisplatin resistance by acting on molecules or/and pathways related to apoptosis, autophagy, hypoxia, cancer stem cells, NF-κB, and Notch1. It appears that the modulation of relevant microRNAs can effectively re-sensitize cancer cells to cisplatin regimen in certain types of cancers including breast, colorectal, gastric, liver, lung, ovarian, prostate, testicular, and thyroid cancers.

pharmacology & pharmacy
The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

Xun Chen,Sufang Kuang,Yi He,Hongyu Li,Chen Yi,Yiming Li,Chao Wang,Guanhui Chen,Shangwu Chen,Dongsheng Yu

DOI: https://doi.org/10.3390/metabo12050389

IF: 4.1

2022-04-25

Metabolites

Abstract:Metabolic reprogramming is one of the hallmarks of a tumor. It not only promotes the development and progression of tumor but also contributes to the resistance of tumor cells to chemotherapeutics. The difference in the metabolism between drug-resistant and sensitive tumor cells indicates that drug-resistant tumor cells have experienced metabolic adaptation. The metabolic response induced by chemotherapy is dynamic, but the early metabolic response of tumor cells to anticancer drugs and the effect of an initial response on the development of drug resistance have not been well studied. Early metabolic intervention may prevent or slow down the development of drug resistance. The differential metabolic responses of normal cells and tumor cells to drugs are unclear. The specific metabolites or metabolic pathways of tumor cells to chemotherapeutic drugs can be used as the target of metabolic intervention in tumor therapy. In this study, we used comparative metabolomics to analyze the differential metabolic responses of oral cancer cells and normal oral epithelial cells to short-term cisplatin exposure, and to identify the marker metabolites of early response in oral cancer cells. Oral cancer cells showed a dynamic metabolic response to cisplatin. Seven and five metabolites were identified as specific response markers to cisplatin exposure in oral cancer cell SCC-9 and normal oral epithelial cell HOEC, respectively. Glyoxylate and dicarboxylate metabolism and fructose, malate, serine, alanine, sorbose and glutamate were considered as specific enriched metabolic pathways and biomarkers of SCC-9 cells in response to cisplatin, respectively. The existence of differential metabolic responses lays a foundation for tumor chemotherapy combined with metabolic intervention.

biochemistry & molecular biology
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer

Xin Cui,Juan Xu,Xuemei Jia

DOI: https://doi.org/10.1186/s12967-024-05770-y

IF: 8.44

2024-10-28

Journal of Translational Medicine

Abstract:Ovarian cancer is a prevalent gynecologic malignancy with the second-highest mortality rate among gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for ovarian cancer; however, a majority of patients with ovarian cancer experience relapse and develop platinum resistance following initial treatment. Despite extensive research on the mechanisms of platinum resistance at the nuclear level, the issue of platinum resistance in ovarian cancer remains largely unresolved. It is noteworthy that mitochondrial DNA (mtDNA) exhibits higher affinity for platinum compared to nuclear DNA (nDNA). Mutations in mtDNA can modulate tumor chemosensitivity through various mechanisms, including DNA damage responses, shifts in energy metabolism, maintenance of Reactive Oxygen Species (ROS) homeostasis, and alterations in mitochondrial dynamics. Concurrently, retrograde signals produced by mtDNA mutations and their subsequent cascades establish communication with the nucleus, leading to the reorganization of the nuclear transcriptome and governing the transcription of genes and signaling pathways associated with chemoresistance. Furthermore, mitochondrial translocation among cells emerges as a crucial factor influencing the effectiveness of chemotherapy in ovarian cancer. This review aims to explore the role and mechanism of mitochondria in platinum resistance, with a specific focus on mtDNA mutations and the resulting metabolic reprogramming, ROS regulation, changes in mitochondrial dynamics, mitochondria-nucleus communication, and mitochondrial transfer.

medicine, research & experimental
Cisplatin resistance-related multi-omics differences and the establishment of machine learning models

Qihai Sui,Zhencong Chen,Zhengyang Hu,Yiwei Huang,Jiaqi Liang,Guoshu Bi,Yunyi Bian,Mengnan Zhao,Cheng Zhan,Zongwu Lin,Qun Wang,Lijie Tan

DOI: https://doi.org/10.1186/s12967-022-03372-0

2022-04-11

Abstract:Objectives: Platinum-based chemotherapies are currently the first-line treatment of non-small cell lung cancer. This study will improve our understanding of the causes of resistance to cisplatin, especially in lung adenocarcinoma (LUAD) and provide a reference for therapeutic decisions in clinical practice. Methods: Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA) and Zhongshan hospital affiliated to Fudan University (zs-cohort) were used to identify the multi-omics differences related to platinum chemotherapy. Cisplatin-resistant mRNA and miRNA models were constructed by Logistic regression, classification and regression tree and C4.5 decision tree classification algorithm with previous feature selection performed via least absolute shrinkage and selection operator (LASSO). qRT-PCR and western-blotting of A549 and H358 cells, as well as single-cell Seq data of tumor samples were applied to verify the tendency of certain genes. Results: 661 cell lines were divided into three groups according to the IC50 value of cisplatin, and the top 1/3 (220) with a small IC50 value were defined as the sensitive group while the last 1/3 (220) were enrolled in the insensitive group. TP53 was the most common mutation in the insensitive group, in contrast to TTN in the sensitive group. 1348 mRNA, 80 miRNA, and 15 metabolites were differentially expressed between 2 groups (P < 0.05). According to the LASSO penalized logistic modeling, 6 of the 1348 mRNAs, FOXA2, BATF3, SIX1, HOXA1, ZBTB38, IRF5, were selected as the associated features with cisplatin resistance and for the contribution of predictive mRNA model (all of adjusted P-values < 0.001). Three of 6 (BATF3, IRF5, ZBTB38) genes were finally verified in cell level and patients in zs-cohort. Conclusions: Somatic mutations, mRNA expressions, miRNA expressions, metabolites and methylation were related to the resistance of cisplatin. The models we created could help in the prediction of the reaction and prognosis of patients given platinum-based chemotherapies.
Abstract A033: The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer

Tise Suzuki,Wanqiu Chen,Charles Wang,Juli Unternaehrer

DOI: https://doi.org/10.1158/1538-7445.ovarian23-a033

IF: 11.2

2024-03-05

Cancer Research

Abstract:High-grade serous ovarian cancer (HGSOC) remains the deadliest cancer of the female reproductive system. Among the many treatment alternatives, platinum-based therapies have been ubiquitous. However, even though initial response is favorable, most patients experience relapse and chemoresistance. Many studies have highlighted the role of epithelial-mesenchymal transition (EMT) in contributing to chemoresistance. In fact, the EMT transcription factor SNAI1 (Snail) has been associated with the development of aggressive disease. Nevertheless, further studies are necessary to understand the underlying mechanisms by which Snail contributes to recurrence and resistance. Thus, our goal is to develop a clinically relevant model of chemoresistance in which to study the transcriptional landscape and gene signatures related to EMT, platinum resistance, and recurrence in HGSOC. After acquisition and characterization of a HGSOC patient sample, cells were continuously exposed to increasing concentrations of cisplatin in vitro, until approximately a tenfold increase in IC-50 relative to parental cells was achieved. RNA-seq analysis comparing the patient-derived sensitive and resistant cell line pair identified over 4,000 genes that were differentially expressed. Furthermore, gene expression was evaluated against a database of genes associated with platinum resistance, revealing 273 genes linked with mechanisms of apoptosis, extracellular matrix signaling, immune response, cancer stemness, EMT, among others. Additionally, we analyzed previously published chromatin immunoprecipitation-sequencing (ChIP-seq) studies for Snail to determine the potential mechanism of EMT-induced therapy resistance. Our results indicate that most of the genes associated with platinum resistance mechanisms were identified by more than two Snail ChIP-seq studies, indicating their potential for being regulated. Furthermore, to establish whether such genes could also be regulated in HGSOC, we compared our findings to ATAC-seq studies done in ovarian cancer cell lines. Data obtained from these analyses will be used in the future assessment of Snail's direct regulation of these pathways and functions. Citation Format: Tise Suzuki, Wanqiu Chen, Charles Wang, Juli Unternaehrer. The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A033.

oncology
PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback

Luyan Shen,Li Zhou,Meihui Xia,Nan Lin,Jiaoyan Ma,Delu Dong,Liankun Sun

DOI: https://doi.org/10.1016/j.yexcr.2020.112369

IF: 4.145

2021-01-01

Experimental Cell Research

Abstract:<p>Mitochondria play an important role in effective cell energy production and cell survival under stress conditions, such as treatment with chemotherapeutic drugs. Mitochondrial biogenesis is increased in ovarian cancer tissues, which is accompanied by alteration of mitochondrial energy metabolism, structure, and dynamics. These factors are involved in tumorigenesis and apoptosis resistance, highlighting the role of mitochondria in resisting cisplatin toxicity. Cisplatin-resistant ovarian cancer cells are dependent on mitochondrial OXPHOS for energy supply, and intracellular PGC1α-mediated mitochondrial biogenesis levels are increased in this cell line, indicating the important role of mitochondrial oxidative phosphorylation in cisplatin resistance. As PGC1α is a key molecule for integrating and coordinating nuclear DNA and mitochondrial DNA transcriptional machinery, an investigation into the regulatory mechanism PGC1α in mitochondrial energy metabolism via transcription may provide new clues for solving chemotherapy resistance. In the present study, it was demonstrated that inhibiting the expression of PGC1α decreased nuclear and mitochondrial DNA transcription factor expression, leading to increased lactic acid production and decreased cellular oxygen consumption and mitochondrial oxidative phosphorylation. Furthermore, mitochondrial stress-induced ROS production, as a feedback signal from mitochondria to the cell nucleus, increased PGC1α expression in SKOV3/DDP cells, which was involved in mitochondrial oxidative phosphorylation regulation. Collectively, the present study provides evidence that PGC1α-mediated nuclear and mitochondrial transcription feedback regulates energy metabolism and is involved in ovarian cancer cells escaping apoptosis during cisplatin treatment.</p>

oncology,cell biology
Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.

M. Berger,G. Masters,J. Singleton,M. S. Scully,Lisa Grimm,D. Soltis,E. Albone

DOI: https://doi.org/10.1089/CBR.2005.20.589

2005-12-01

Cancer Biotherapy and Radiopharmaceuticals

Abstract:776.1 is a murine IgG1 monoclonal antibody to the human ovarian cancer antigen CA 125 that has the unique property of having a clear preference for binding to the cell-associated form of the antigen. We have examined the tumor localization properties and efficacy of 776.1 in a subcutaneous OVCAR-3 xenograft mouse model of human ovarian cancer. Biodistribution experiments using (125)I-labeled 776.1 demonstrated a peak uptake in tumors at 72 hours postinjection, with an average of 17.7% of injected dose per gram localized to the tumor. Little uptake in other organs was observed. Further experiments using CA 125-transfected syngeneic tumors, as well as an immunoprecipitation assay using human chimeric 776.1, both clearly demonstrated that 776.1 localizes to the tumor in a CA 125-dependent manner. DOTA-776.1 (1,4,7,10-tetraazacyclododecane-N,N',N",N'" tetraacetic acid-conjugated 776.1) was labeled with (90)Y and used in efficacy studies. [(90)Y-DOTA]776.1 at a single dose of 150 microCi was able to mediate efficient reduction of tumor growth, with regression observed in a subset of animals for a period ranging from 3 to 48 days, equivalent to 3 weekly administrations of cisplatin at 6 mg/kg. No significant regression was observed in groups receiving [(90)Y-DOTA]MOPC-21 control antibody at any dose. These results suggest that 776.1 may be a promising radioimmunotherapeutic agent for the treatment of human ovarian cancer.

Nitroquinolones with broad-spectrum antimycobacterial activity in vitro.

Mitochondrial DNA sequences and transcriptomic profiles for elucidating the genetic underpinnings of cisplatin responsiveness in oral squamous cell carcinoma

Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell.

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Nuclear TOP1MT Confers Cisplatin Resistance via Pseudogene in HNSCC

PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis

Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells

Impairment of Drug Response Cascades, by DNA Methylation, in Platinum-Resistant Ovarian Cancer.

Negotiated Interfaces for Software Reuse

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy

A Genome Wide CRISPR Profiling Approach Identifies Mechanisms of Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma.

Molecular mechanisms of cisplatin resistance

Proteomic Analyses of Sirt1-Mediated Cisplatin Resistance in OSCC Cell Line

Long-Term Cisplatin Exposure Promotes Methylation of the OCT1 Gene in Human Esophageal Cancer Cells

The role of microRNA in cisplatin resistance or sensitivity

The Differential Metabolic Response of Oral Squamous Cell Carcinoma Cells and Normal Oral Epithelial Cells to Cisplatin Exposure

Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer

Cisplatin resistance-related multi-omics differences and the establishment of machine learning models

Abstract A033: The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer

PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback

Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer.